Treace Announces Participation at Stifel 2024 Healthcare Conference

Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI), a medical technology company focused on surgical treatment of bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® Procedures, announced its participation in the Stifel 2024 Healthcare Conference. The company's CEO John T. Treace and CFO Mark L. Hair will participate in a fireside chat on November 19, 2024, at 8:00 am ET. A live webcast and replay will be available on the company's investor relations website.

PONTE VEDRA, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty^® and Adductoplasty^® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, beginning at approximately 8:00 am ET.

A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/.

Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net

FAQ

When is Treace Medical Concepts (TMCI) presenting at the Stifel 2024 Healthcare Conference?

Treace Medical Concepts (TMCI) will present at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 8:00 am ET.

Who will represent TMCI at the Stifel 2024 Healthcare Conference?

CEO John T. Treace and CFO Mark L. Hair will represent TMCI at the conference in a fireside chat format.

How can investors watch TMCI's presentation at the Stifel Healthcare Conference?

Investors can watch the live webcast and replay of the fireside chat through Treace's investor relations website at https://investors.treace.com/.